Clearmind Medicine Establishes Third R&D Partnership With the Hebrew University

Rhea-AI Summary

Clearmind Medicine Inc. (CMNDF) has announced a new agreement to collaborate with the Hebrew University of Jerusalem in Israel. This partnership aims to advance research on novel patentable psychedelics for potential treatment of mental health disorders. The company's focus lies in developing psychedelic-derived therapeutics to address significant health issues, including alcohol use disorder. Clearmind possesses four patent families and intends to expand its intellectual property portfolio.

Positive

• New agreement with Hebrew University to fund research on psychedelics.
• Focus on patentable psychedelic molecules for mental health treatment.
• Existing portfolio of four patent families indicates innovation potential.

Negative

• None.

Research will focus on developing novel patentable psychedelics as potential drug candidates

TORONTO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF) (“Clearmind” or the “Company”), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, is pleased to announce it has entered an new agreement to fund further research and development projects with the Hebrew University of Jerusalem, Israel, focused on developing novel and patentable psychedelic molecules in search of potential drug candidates for the treatment of mental health disorders.

About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

The Company’s intellectual portfolio currently consists of four patent families. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol “CMND”, the Frankfurt Stock Exchange under the symbol “CWYO” and on the OTC pink under the symbol “CMNDF”.

For further information, please contact:
Investor Relations,
Email: invest@clearmindmedicine.com
Telephone: (778) 400-5347
General Inquiries,
Info@Clearmindmedicine.com
www.Clearmindmedicine.com

FORWARD-LOOKING STATEMENTS:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company’s business strategy. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of the Company shall be considered highly speculative.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

FAQ

What did Clearmind Medicine announce on January 10, 2022?

Clearmind Medicine announced a new agreement to fund research with the Hebrew University of Jerusalem for developing novel psychedelic molecules.

What is the primary focus of Clearmind Medicine?

Clearmind Medicine focuses on developing psychedelic-derived therapeutics to address mental health disorders such as alcohol use disorder.

How many patent families does Clearmind currently own?

Clearmind currently owns four patent families related to its psychedelic compounds.

What stock exchanges list Clearmind Medicine?

Clearmind Medicine is listed on the Canadian Securities Exchange as CMND, the Frankfurt Stock Exchange as CWYO, and on the OTC Pink as CMNDF.